The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia
Abstract
Complement plays an important role in the immunotherapeutic action of the anti-CD20 mAb rituximab, and therefore we investigated whether complement might be the limiting factor in rituximab therapy. Our in vitro studies indicate that at high cell densities, binding of rituximab to human CD20+ cells leads to loss of complement activity and consumption of component C2. Infusion of rituximab in chronic lymphocytic leukemia patients also depletes complement; sera of treated patients have reduced capacity to C3b opsonize and kill CD20+ cells unless supplemented with normal serum or component C2. Initiation of rituximab infusion in chronic lymphocytic leukemia patients leads to rapid clearance of CD20+ cells. However, substantial numbers of B cells, with significantly reduced levels of CD20, return to the bloodstream immediately after rituximab infusion. In addition, a mAb specific for the Fc region of rituximab does not bind to these recirculating cells, suggesting that the rituximab-opsonized cells were temporarily sequestered by the mononuclear phagocytic system, and then released back into the circulation after the rituximab-CD20 complexes were removed by phagocytic cells. Western blots provide additional evidence for this escape mechanism that appears to occur as a consequence of CD20 loss. Treatment paradigms to prevent this escape, such as use of engineered or alternative anti-CD20 mAbs, may allow for more effective immunotherapy of chronic lymphocytic leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Self-citationDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Czuczman, M. S., Grillo-López, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., & Varns, C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.268 · Cited by 856
Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604
Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia
O’Brien, S. M., Kantarjian, H., Thomas, D. A., Giles, F. J., Freireich, E. J., Cortes, J., Lerner, S., & Keating, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2165 · Cited by 586
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
The role of membrane receptors for C3b and C3d in phagocytosis.
Ehlenberger, A. G., & Nussenzweig, V (1977) · The Journal of experimental medicine · doi:10.1084/jem.145.2.357 · Cited by 534
Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G., Grever, M. R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2153 · Cited by 508
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma
Hainsworth, J. D., Litchy, S., Burris, H. A., Scullin, D. C., Corso, S. W., Yardley, D. A., Morrissey, L., & Greco, F. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.674 · Cited by 416
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v99.3.1038 · Cited by 367
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Huhn, D. (2001) · Blood · doi:10.1182/blood.v98.5.1326 · Cited by 347
Levels of expression of CD19 and CD20 in chronic B cell leukaemias.
Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., & Catovsky, D. (1998) · Journal of Clinical Pathology · doi:10.1136/jcp.51.5.364 · Cited by 325
Grillo-López, A. J., White, C. A., Varns, C., Shen, D., Wei, A., McClure, A., & Dallaire, B. K. (1999) · PubMed · Cited by 298
Griffin, F. M., Griffin, J. A., & Silverstein, S. C. (1976) · The Journal of experimental medicine · doi:10.1084/jem.144.3.788 · Cited by 295
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Harjunpää, Junnikkala, & Meri (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00745.x · Cited by 256
The mechanisms of action of rituximab in the elimination of tumor cells
Johnson, P., & Glennie, M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50025 · Cited by 247
CD20‐mediated apoptosis: signalling through lipid rafts
Deans, J. P., Li, H., & Polyak, M. J. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01495.x · Cited by 233
Schreiber, A. D., & Frank, M. M. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106846 · Cited by 206
Bellosillo, B., Villamor, N., López-Guillermo, A., Marcé, S., Esteve, J., Campo, E., Colomer, D., & Montserrat, E. (2001) · Blood · doi:10.1182/blood.v98.9.2771 · Cited by 205
M. Cardarelli, M. Q. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-001-0247-1 · Cited by 189
Bannerji, R., Kitada, S., Flinn, I. W., Pearson, M., Young, D., Reed, J. C., & Byrd, J. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.012 · Cited by 178
Flieger, D., Renoth, S., Beier, I., Sauerbruch, T., & Schmidt‐Wolf, I. G. H. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1693 · Cited by 166
Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment
Deans, J. P., Robbins, S. M., Polyak, M. J., & Savage, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.344 · Cited by 151
Kennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L., & Taylor, R. P. (2003) · Blood · doi:10.1182/blood-2002-03-0876 · Cited by 141
Self-citationStockmeyer, B., Dechant, M., van Egmond, M., Tutt, A. L., Sundarapandiyan, K., Graziano, R. F., Repp, R., Kalden, J. R., Gramatzki, M., Glennie, M. J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5954 · Cited by 121
Foran, J. M., Norton, A. J., Micallef, I. N. M., Taussig, D. C., Amess, J. A. L., Rohatiner, A. Z. S., & Lister, T. A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03019.x · Cited by 113
Clinical applications of anti-CD20 antibodies
Gopal, A. K., & Press, O. W. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90164-6 · Cited by 97
Preclinical and phase I and II trials of rituximab.
Maloney, D. (1999) · PubMed · Cited by 95
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy
Weide, R., Heymanns, J., Pandorf, A., & Köppler, H. (2003) · Lupus · doi:10.1191/0961203303lu449cr · Cited by 85
Complement : a practical approach
Dodds, A. W., & Sim, R. B. (1997) · IRL Press eBooks · Cited by 56
Fries, L. F., Siwik, S. A., Malbrán, A., & Frank, M. M. (1987) · PubMed Central · Cited by 46
The covalent interaction of C3 with IgG immune complexes
Vivanco, F., Muñoz, E., Vidarte, L., & Pastor‐Vargas, C. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00105-4 · Cited by 32
Kuhn, S., Nardin, A., Klebba, P. E., & Taylor, R. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.5088 · Cited by 28
Self-citationMorley, B. J., & Walport, M. J. (2000) · Elsevier eBooks · doi:10.1016/b978-012733360-1/50003-8 · Cited by 18
Cited by
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Self-citation
Metadata
- Authors
- Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-03-01
- Volume
- 172
- Issue
- 5
- Pages
- 3280-3288
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1897592311
- Cited by
- 359
- References
- 42
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.